ROCKVILLE, Md., April 18, 2016 /PRNewswire/ -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing next-generation immunotherapy platforms will be participating at the Maryland Regional Biotech Forum taking place today and tomorrow in Gaithersburg, MD.
ITI Chief Executive Officer Bill Hearl, PhD will be participating in a panel at 10:30 am ET tomorrow focused on the promises and challenges of personalized cancer medicine. Expect to hear about precision diagnosis and treatment of cancer at the molecular level. Dr. Hearl's participation follows an exclusive worldwide licensing agreement concerning LAMP-based immunotherapy for the treatment or prevention of any and all allergic diseases for people. His company is now actively examining applications of the LAMP technology platform in cancer. LAMP technology uniquely re-educates the immune system, making any vaccine more effective and early results are promising.
"We are pleased to join CytImmune, INOVA, MedImmune and Precision for Medicine, in this important discussion on transformative oncology research advancements," said ITI Chief Executive Officer Bill Hearl, PhD. "As we move forward in clinical studies for LAMP-based nucleic acid immunotherapy, we are also excited for the future and for the potential to dramatically advance cancer vaccine efficacy."
About LAMP-based Nucleic Acid Immunotherapy and Immunomic Therapeutics
LAMP encodes the Lysosomal Associated Membrane Protein. This allows nucleic acid immunotherapy (DNA or RNA) to utilize the body's natural biochemistry, with the aim of developing a complete immune response including antibody production, cytokine release and critical immunological memory. The ability to activate a complete immune response could give LAMP technology potential across a number of diseases, including cancer immunotherapy, allergy and infectious diseases.
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These disruptive technologies have the potential to fundamentally improve how we use immunotherapy for cancer, allergies and animal health. Headquartered in Hershey, PA with lab facilities in Rockville, MD, ITI has entered into a significant licensing agreement with Astellas Pharma Inc., to explore the use of LAMP-vax, a next-generation immunotherapy platform, for use to prevent and treat allergic diseases. ITI believes that LAMP-based nucleic acid immunotherapy may have the potential to broaden the current use of cancer immunotherapy. Preclinical data is currently being developed to explore how LAMP nucleic acid constructs could both amplify and activate the immune response in highly immunogenic tumor types and also be used to create robust immune responses to tumor types that otherwise do not provoke an immune response. For information about ITI and LAMP Technology, visit www.immunomix.com.
SOURCE Immunomic Therapeutics, Inc.